Journal article
Combination Versus Monotherapy for Carbapenem-Resistant Acinetobacter Species Serious Infections: A Prospective IPTW Adjusted Cohort Study
- Abstract:
- Introduction: International guidelines recommend definitive combination antibiotic therapy for the management of serious infections involving carbapenem-resistant Acinetobacter (CRAB) species. The commonly available combination options include high-dose sulbactam, polymyxins, tetracyclines, and cefiderocol. Scanty prospective data exist to support this approach. Methods: Patients with CRAB bacteraemia, ventilator-associated pneumonia (VAP), or both were categorized based on whether they received combination therapy or monotherapy. The 30-day mortality was compared between the two groups. Inverse probability treatment weighting (IPTW) was done using propensity score (PS) for a balanced comparison between groups. Results: Between January 2021 and May 2023, of the 161 patients with CRAB bacteraemia (n = 55, 34.2%), VAP (n = 46, 28.6%), or both (n = 60, 37.3%) who received appropriate intravenous antibiotic therapy, 70% (112/161) received monotherapy, and the rest received combination therapy. The overall 30-day mortality was 62% (99/161) and not different (p = 0.76) between the combination therapy (31/49, 63.3%) and monotherapy (68/112, 60.7%) groups. The propensity score matching using IPTW did not show a statistical difference (p = 0.47) in 30-day mortality for receiving combination therapy with an adjusted odds ratio (OR) P of 1.29 (0.64, 2.58). Conclusion: Combination therapy for CRAB infections needs further study in a randomised controlled trial, as this observational study showed no difference in 30-day mortality between monotherapy and combination therapy.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 307.1KB, Terms of use)
-
(Preview, Other, pdf, 158.4KB, Terms of use)
-
- Publisher copy:
- 10.1007/s40121-024-01042-w
Authors
+ International Society for Infectious Diseases
More from this funder
- Funder identifier:
- https://ror.org/02vrwn188
- Publisher:
- Springer
- Journal:
- Infectious Diseases and Therapy More from this journal
- Volume:
- 13
- Issue:
- 11
- Pages:
- 2351-2362
- Publication date:
- 2024-09-25
- Acceptance date:
- 2024-09-02
- DOI:
- EISSN:
-
2193-6382
- ISSN:
-
2193-8229
- Language:
-
English
- Keywords:
- Pubs id:
-
2036045
- Local pid:
-
pubs:2036045
- Source identifiers:
-
2363761
- Deposit date:
-
2024-10-24
- ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.
Terms of use
- Copyright date:
- 2024
If you are the owner of this record, you can report an update to it here: Report update to this record